Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
Completed · Phase 2 · Has a placebo group
Conditions studied: Healthy
In brief
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood Clotting Time (WBCT).
Key facts
- Study ID
- NCT03172910
- Run by
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
- People needed
- 69
- Starts
- 2017-05-08
- Expected to finish
- 2019-11-12
- Last updated by the study team
- 2025-09-02
Who can join
Age: 50 and older, up to 75. Sex: any. Healthy volunteers: accepted.
Where it is running
- Frontage Clinical Services Inc. — Secaucus, New Jersey, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.